Personalis (NASDAQ:PSNL) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Personalis (NASDAQ:PSNL) from a hold rating to a sell rating in a report released on Saturday.

Other analysts have also issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Wednesday, October 8th. Morgan Stanley increased their price objective on Personalis from $9.00 to $11.00 and gave the company an “equal weight” rating in a research report on Monday, December 1st. HC Wainwright boosted their target price on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Guggenheim increased their price target on shares of Personalis from $6.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Finally, Lake Street Capital restated a “buy” rating and set a $11.00 price objective on shares of Personalis in a report on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.57.

Personalis Trading Down 1.4%

NASDAQ:PSNL opened at $7.85 on Friday. The firm has a market capitalization of $697.08 million, a PE ratio of -8.92 and a beta of 1.96. Personalis has a 1 year low of $2.83 and a 1 year high of $11.40. The firm’s fifty day simple moving average is $8.82 and its 200 day simple moving average is $7.19.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. The company had revenue of $14.50 million during the quarter, compared to analysts’ expectations of $13.31 million. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. As a group, analysts anticipate that Personalis will post -1.4 EPS for the current fiscal year.

Insider Transactions at Personalis

In other Personalis news, CEO Christopher M. Hall sold 29,612 shares of Personalis stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total transaction of $266,211.88. Following the sale, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at approximately $1,334,889.14. The trade was a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Aaron Tachibana sold 103,668 shares of the stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total value of $1,117,541.04. Following the completion of the transaction, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at approximately $1,772,857.24. The trade was a 38.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Personalis

Several institutional investors and hedge funds have recently made changes to their positions in the company. Kennedy Capital Management LLC increased its position in shares of Personalis by 196.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after purchasing an additional 1,281,695 shares in the last quarter. Geode Capital Management LLC grew its stake in Personalis by 165.6% during the second quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock worth $8,960,000 after buying an additional 851,422 shares during the last quarter. ARK Investment Management LLC increased its holdings in shares of Personalis by 11.3% during the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after buying an additional 802,268 shares in the last quarter. Aberdeen Group plc increased its holdings in shares of Personalis by 35.7% during the third quarter. Aberdeen Group plc now owns 2,387,947 shares of the company’s stock worth $15,569,000 after buying an additional 628,450 shares in the last quarter. Finally, Blue Water Life Science Advisors LP raised its stake in shares of Personalis by 42.6% in the second quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock valued at $10,997,000 after acquiring an additional 500,900 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.